See What HealthDay Can Do For You
Contact Us

Mantle Cell Lymphoma Rate on Rise in Recent Years

During 13-year study period, incidence higher in men, whites, older individuals; often diagnosed late

THURSDAY, July 10 (HealthDay News) -- In a sample of patients diagnosed with non-Hodgkin's lymphoma between 1992 and 2004, mantle cell lymphoma accounted for 2.8 percent of the cases, according to research published in the August 15 issue of Cancer.

Yuhong Zhou, M.D., of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues used Surveillance, Epidemiology, and End Results (SEER) registries to analyze data from patients in 13 geographic areas in the United States diagnosed with mantle cell lymphoma (MCL) during this period. Their analysis included 87,166 cases.

The researchers report that the age-adjusted incidence rate of MCL rose from 0.27 of 100,000 in 1992 to 0.69 of 100,000 in 2004. The incidence was higher in men, and also higher in whites than in blacks. The incidence also increased with age, with the lowest rates in those under the age of 50, and the highest in patients older than 80. Most patients (74.6 percent) were diagnosed with stage III and IV disease.

"The current study demonstrated incidence and mortality curves ran parallel, indicating that increased incidence rate is accompanied by higher mortality. However, this finding does not reflect the newer, highly effective therapies that have been tested and approved since 2004. During this time period, novel efficacious therapies were approved and used for patients with MCL. For example, rituximab (a chimeric monoclonal anti-CD20 antibody) revolutionized the treatment of non-Hodgkin's lymphoma) and improved survival responses," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing
undefined
undefinedundefined